Abstract
Background: Toxic optic neuropathies (TONs) often present with a gradual and bilateral decrease in visual acuity, scotomas and optic disc pallor. Obtaining an accurate history is the critical first step in determining the etiology of TONs.
Methods: This updated review contains a thorough analysis of the current PubMed-indexed literature on the most common agents responsible for TONs, including methanol, ethambutol, amiodarone, linezolid, tumor necrosis factor alpha inhibitors and phosphodiesterase 5 inhibitors. Results: The reviewed articles are mainly case reports presenting new and controversial aspects of the above agents. New treatment strategies, such as erythropoietin for methanol optic neuropathy, are being proposed for TONs, a condition that was previously regarded as untreatable. Conclusion: TONs could cause significant disability due to visual impairment. In case of early diagnosis and drug withdrawal, most TONs are treatable. Patients need to be appropriately counseled, and prescribing physicians should be especially made aware of TON-inducing medications.Keywords: Amiodarone, ethambutol, linezolid, methanol, phosphodiesterase 5 inhibitors, toxic optic neuropathy, tumor necrosis factor alpha inhibitors.
Current Pharmaceutical Design
Title:An Updated Review on the Most Common Agents Causing Toxic Optic Neuropathies
Volume: 23 Issue: 4
Author(s): Weronika Wasinska-Borowiec, Kaveh Abri Aghdam, Jukka Matias Saari and Andrzej Grzybowski
Affiliation:
Keywords: Amiodarone, ethambutol, linezolid, methanol, phosphodiesterase 5 inhibitors, toxic optic neuropathy, tumor necrosis factor alpha inhibitors.
Abstract: Background: Toxic optic neuropathies (TONs) often present with a gradual and bilateral decrease in visual acuity, scotomas and optic disc pallor. Obtaining an accurate history is the critical first step in determining the etiology of TONs.
Methods: This updated review contains a thorough analysis of the current PubMed-indexed literature on the most common agents responsible for TONs, including methanol, ethambutol, amiodarone, linezolid, tumor necrosis factor alpha inhibitors and phosphodiesterase 5 inhibitors. Results: The reviewed articles are mainly case reports presenting new and controversial aspects of the above agents. New treatment strategies, such as erythropoietin for methanol optic neuropathy, are being proposed for TONs, a condition that was previously regarded as untreatable. Conclusion: TONs could cause significant disability due to visual impairment. In case of early diagnosis and drug withdrawal, most TONs are treatable. Patients need to be appropriately counseled, and prescribing physicians should be especially made aware of TON-inducing medications.Export Options
About this article
Cite this article as:
Wasinska-Borowiec Weronika, Aghdam Abri Kaveh, Saari Matias Jukka and Grzybowski Andrzej, An Updated Review on the Most Common Agents Causing Toxic Optic Neuropathies, Current Pharmaceutical Design 2017; 23 (4) . https://dx.doi.org/10.2174/1381612823666170124113826
DOI https://dx.doi.org/10.2174/1381612823666170124113826 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Simvastatin is Protective During Staphylococcus aureus Pneumonia
Current Pharmaceutical Biotechnology Evaluation of Two Recombinant Plasminogen Activators in Massive Pulmonary Embolism Model and Potato Carboxypeptidase Inhibitor (PCI) role in Inhibition of Thrombin Activatable Fibrinolysis Inhibitor TAFIa in Lungs
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Essentials in the Treatment of COVID-19
Anti-Infective Agents Coronavirus Disease 2019 (COVID-19) and Pregnancy: A Narrative Review
Current Pediatric Reviews Targeting Drugs to APJ Receptor: The Prospect of Treatment of Hypertension and Other Cardiovascular Diseases
Current Drug Targets Targeting Heme Oxygenase-1 in Vascular Disease
Current Drug Targets ADAM28 as a Target for Human Cancers
Current Pharmaceutical Design Remediation of Cellular Hypoxic Damage by Pharmacological Agents
Current Pharmaceutical Design Pancreatic Cancer: Promises and Failures of Target Therapies
Reviews on Recent Clinical Trials Potential Use of Polymeric Nanoparticles for Drug Delivery Across the Blood-Brain Barrier
Current Medicinal Chemistry Lone Atrial Fibrillation: Electrophysiology, Risk Factors, Catheter Ablation and Other Non-pharmacologic Treatments
Current Pharmaceutical Design Novel Anti-arrhythmic Medications in the Treatment of Atrial Fibrillation
Current Cardiology Reviews Role of Endogenous Granulocyte-Macrophage Colony Stimulating Factor Following Stroke and Relationship to Neurological Outcome
Current Neurovascular Research Immune Monitoring in Organ Transplantation Using Neopterin
Current Drug Metabolism Cardiovascular Magnetic Resonance for Evaluation of Heart Involvement in ANCA-Associated Vasculitis. A Luxury or a Valuable Diagnostic Tool?
Inflammation & Allergy - Drug Targets (Discontinued) Fontan Circulation Might be Associated with Peripartum Cardiomyopathy: A Review of Mechanistic and Clinical Aspects
Current Cardiology Reviews Pharmacologically Targeting the Primary Defect and Downstream Pathology in Duchenne Muscular Dystrophy
Current Gene Therapy Non-Vitamin K Oral Anticoagulant Drugs for Stroke Prevention in Patients with Atrial Fibrillation and Chronic Kidney Disease
Current Medicinal Chemistry Clinical Potential of Neuropeptide Y Receptor Ligands in the Treatment of Epilepsy
Current Topics in Medicinal Chemistry Treatment of Cardiovascular Risk Factors in Women
Current Medicinal Chemistry